Retinopathy of Prematurity clinical trials at UCLA
2 in progress, 1 open to eligible people
Bevacizumab Treatment For Type 1 ROP
open to eligible people ages up to 6 months
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.
Los Angeles, California and other locations
Clinical Efficacy and Safety Study of OHB-607 in Preventing Chronic Lung Disease in Extremely Premature Infants
Sorry, in progress, not accepting new patients
The purpose of this study is to determine if an investigational drug can reduce the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
Los Angeles, California and other locations
Our lead scientists for Retinopathy of Prematurity research studies include Stacy L Pineles, MD Meena Garg.
Last updated: